RxDoctor Payments Data

Ronald Travitz, MD

Internal Medicine · Salisbury, MDNPI 1841384625

Payments from drug & device makers

$460in general payments, 2019–2025

Across 29 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$111
  • Abbott$101
  • GSK$50
  • Pfizer$43
  • Amgen$36
  • OPKO Pharmaceuticals, LLC$22
  • plus $97 from 6 others

What the payments were for

  • Food & beverage$43995%
  • Education$225%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$460 in reported general payments places this provider in the 60th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$1,037
Medicare patients
75
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$60,114
EliquisApixaban49$55,772
JanuviaSitagliptin Phosphate39$51,069
XareltoRivaroxaban35$45,476
TrulicityDulaglutide23$29,152
CreonLipase/Protease/Amylase11$25,745
JardianceEmpagliflozin24$22,760
MounjaroTirzepatide14$21,664
Breo ElliptaFluticasone/Vilanterol28$13,498
EntrestoSacubitril/Valsartan16$11,574
Advair HfaFluticasone Propion/Salmeterol11$7,278
Atorvastatin Calcium462$6,874
Losartan Potassium411$5,674
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,658
Rosuvastatin Calcium202$5,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$111$60,11445 claims
PfizerEliquis, Paxlovid$43$59,75568 claims
MerckJanuvia$11$51,06939 claims
Lilly USA, LLCTrulicity, Mounjaro$13$50,81737 claims
Johnson & JohnsonXarelto$18$45,47635 claims
GSKBreo Ellipta, Anoro Ellipta$50$19,15641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →